Concepedia

Stephen Grossman

SG

4

Publications

403

Citations

4

H-Index

2019

Active since

Affiliations

Takeda (United States)(Current)

Stephen Grossman is an author at Takeda (United States) specializing in t cell immunity, immune regulation, and tumor immunity.

Top concepts

Publications per year

2019–2022

4

Publications

4

Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer

Steven Langston, Stephen Grossman, Dylan B. England et al. · Journal of Medicinal Chemistry · 2021 · 194 citations · Full text

A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models

Eric S. Lightcap, Pengfei Yu, Stephen Grossman et al. · Science Translational Medicine · 2021 · 129 citations · Full text

The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation

Akito Nakamura, Stephen Grossman, Keli Song et al. · Blood · 2022 · 66 citations · Full text

Abstract 3252: TAK-981: A first in class SUMO inhibitor in Phase 1 trials that promotes dendritic cell activation, antigen-presentation, and T cell priming

Mithun Khattar, Keli Song, Stephen Grossman et al. · Cancer Research · 2019 · 14 citations

, , +25

Rows per page

1–4 of 4